BSE: SANOFI - Sanofi India Limited

Rentabilité sur six mois: -12.85%

Calendrier des promotions Sanofi India Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors.

plus de détails
It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

ISIN INE058A01010
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 1.71
Дивиденд ао 68.21
Сайт https://www.sanofiindialtd.com
Цена ао 5592.35
Changement de prix par jour: -0.4488% (5592.35)
Changement de prix par semaine: -6.84% (5976.1)
Changement de prix par mois: -10.28% (6205.25)
Changement de prix sur 3 mois: -18.95% (6869)
Changement de prix sur six mois: -12.85% (6388.45)
Changement de prix par an: -32.38% (8233.25)
Evolution du prix sur 3 ans: -25.95% (7518.15)
Evolution du prix sur 5 ans: -20.95% (7042.75)
Evolution des prix sur 10 ans: 0% (5567.25)
Evolution des prix depuis le début de l'année: -9.08% (6123.05)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 6.55 1
P/BV 18.17 1
P/E 30.59 5
EV/EBITDA 17.69 6
Total: 4.63

Efficacité

Nom Signification Grade
ROA, % 35.16 9
ROE, % 59.39 10
Total: 5.83

Dividendes

Nom Signification Grade
Div yield, % 1.51 3.78
DSI 0.8571 8.57
Total: 4.94

Devoir

Nom Signification Grade
Debt/EBITDA 0.026 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -8.24 0
Rentabilité Ebitda, % 20.55 4
Rentabilité EPS, % 50.5 7
Total: 3.4
Plus de détails

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares MSCI India Small-Cap ETF 0.16695 0.4625 0.96163
SPDR S&P Emerging Markets Small Cap ETF 0.07114 5.46 3.03583
iShares MSCI Emerging Markets Small-Cap ETF 0.04483 7.67 2.7853
Avantis Emerging Markets Value ETF 0.03441 14.12 4.22231
Avantis Responsible Emerging Markets Equity ETF 0.02777 17.6 3.1719
Vanguard FTSE All-World ex-US Small-Cap ETF 0.02 9.39 3.09932
Avantis Emerging Markets Equity ETF 0.01484 8.77 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.0079 15.96 3.34087
Dimensional World ex U.S. Core Equity 2 ETF 0.00469 13.06 3.62488
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00447 12.46 3.59676

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Rodolfo Hrosz MD & Director 17.85M 1967 (58 années)
Mr. M. K. Narayanaswamy B.Com.,A.I.C.W.A. Senior Director of Accounting & Taxation N/A 1955 (70 années)
Mr. Sanjay V. Chavan Head of Country Procurement - India N/A 1962 (63 année)
Ms. Surabhi Kaur People & Culture Director N/A
Ms. Renee Amonkar Additional Whole Time Director N/A
Mr. Rachid Ayari CFO & Whole Time Director N/A
Ms. Flovie Martins Head of Corporate Communications & Corporate Social Responsibility
Nakul Verma Senior Director of Public Affairs
Yasmin Shenoy Senior Director of Regulatory Affairs
Mr. N. Suresh Babu Sales & Customer Engagement Head - Diabetes and Senior Director of Diabetes

Adresse: India, Mumbai, Sanofi House - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.sanofiindialtd.com